Glaucoma remains a chronic and visually debilitating disease that has vast public health implications, as well as pronounced effects on individual quality of life. Going forward, development of new modalities to treat glaucoma will continue to align with trends of other ophthalmic indications—novel drug delivery mechanisms and long-acting medications, less invasive surgical procedures, and even gene-based therapy. For the first time in decades, there has been a major paradigm shift in the way that glaucoma is diagnosed and treated, and commensurate growth in research and development for this indication.

In this whitepaper, Arlene Bagga, MD Medical Director, Ophthalmology PRA Health Sciences shares an overview of glaucoma, including disease impact, pathophysiology, diagnosis, and treatments.

Glaucoma: Under Pressure to Treat

Explore related content and topics